eMedicine Specialties > Dermatology > Mycobacterial Infections

Leprosy

Author: Felisa S Lewis, MD,, Staff Physician, Department of Dermatology, Madigan Army Medical Center
Coauthor(s): Theresa Dressler Conologue, DO, FAAD, Physician, Department of Dermatology, Geisinger Medical Center; Elyse Harrop, MD, Clinical Instructor, Department of Dermatology, Metrohealth Medical Center
Contributor Information and Disclosures

Updated: Feb 4, 2010

Introduction

Background

Leprosy is a chronic granulomatous disease principally affecting the skin and peripheral nervous system. Leprosy is caused by infection with Mycobacterium leprae. Although much improved in the last 25 years, knowledge of the pathogenesis, course, treatment, and prevention of leprosy continues to evolve. The skin lesions and deformities were historically responsible for the stigma attached to leprosy. However, even with proper multidrug therapy (MDT), the consequent sensory and motor damage results in the deformities and disabilities associated with leprosy.

The earliest description of leprosy comes from India around 600 BCE. Leprosy was then described in the Far East around 400 BCE. In the fourth century, leprosy was imported into Europe, where its incidence peaked in the 13th century. Leprosy has now nearly disappeared from Europe. Affected immigrants spread leprosy to North America.

Armauer Hansen discovered M leprae in Norway in 1873. M leprae was the first bacillus to be associated with human disease. Despite this discovery, leprosy was not initially thought to be an infectious disease.

In 2009, the discovery of a new cause of leprosy, Mycobacterium lepromatosis, was announced. Genetically, M leprae and M lepromatosis are very similar, but M lepromatosis causes the diffuse form lepromatous leprosy found in Mexico and the Caribbean.1

Humans are the primary reservoir of M leprae. Animal reservoirs of leprosy have been found in 3 species: 9-banded armadillos, chimpanzees, and mangabey monkeys.

Other eMedicine articles on leprosy include Leprosy (Neurology), Neuropathy of Leprosy, and Leprosy (Infectious Diseases).

Pathophysiology

Leprosy is not a highly infectious disease. The principal means of transmission is by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. Leprosy is not generally spread by means of direct contact through intact skin, although close contacts are most vulnerable. The incubation period for leprosy is 6 months to 40 years or longer. The mean incubation period is 4 years for tuberculoid leprosy and is 10 years for lepromatous leprosy.

The areas most commonly affected by leprosy are the superficial peripheral nerves, skin, mucous membranes of the upper respiratory tract, anterior chamber of the eyes, and the testes. These areas tend to be cool parts of the body. Tissue damage depends on the degree to which cell-mediated immunity is expressed, the type and extent of bacillary spread and multiplication, the appearance of tissue-damaging immunologic complications (ie, lepra reactions), and the development of nerve damage and its sequelae.

M leprae is an obligate intracellular, acid-fast, gram-positive bacillus with an affinity for macrophages and Schwann cells. For Schwann cells in particular, the mycobacteria bind to the G domain of the alpha-chain of laminin 2 (found only in peripheral nerves) in the basal lamina. Their slow replication within the Schwann cells eventually stimulates a cell-mediated immune response, which creates a chronic inflammatory reaction. As a result, swelling occurs in the perineurium, leading to ischemia, fibrosis, and axonal death.

The genomic sequence of M leprae was only completed within the last few years. One important discovery is that although it depends on its host for metabolism, the microorganism retains genes for the formation of a mycobacterial cell wall. Components of the cell wall stimulate a host immunoglobulin M antibody and cell-mediated immune response, while also moderating the bactericidal abilities of macrophages.

The strength of the host's immune system influences the clinical form of the disease. Strong cell-mediated immunity (interferon-gamma, interleukin [IL]–2) and a weak humoral response results in mild forms of disease, with a few well-defined nerves involved and lower bacterial loads. A strong humoral response (IL-4, IL-10) but relatively absent cell-mediated immunity results in lepromatous leprosy, with widespread lesions, extensive skin and nerve involvement, and high bacterial loads. Therefore, a spectrum of disease exists such that cell-mediated immunity dominates in mild forms of leprosy and decreases with increasing clinical severity. Meanwhile, humoral immunity is relatively absent in mild disease and increases with the severity of disease.

Toll-like receptors (TLRs) may also play a role in the pathogenesis of leprosy.2 M leprae activates TLR2 and TLR1, which are found on the surface of Schwann cells, especially with tuberculoid leprosy. Although this cell-mediated immune defense is most active in mild forms of leprosy, it is also likely responsible for the activation of apoptosis genes and, consequently, the hastened onset of nerve damage found in persons with mild disease. Alpha-2 laminin receptors found in the basal lamina of Schwann cells are also a target of entry for M leprae into these cells, while activation of the ErbB2 receptor tyrosine kinase signaling pathway has been identified as a mediator of demyelination in leprosy.3

The activation of macrophages and dendritic cells, both antigen-presenting cells, is involved in the host immune response to M leprae. IL-1beta produced by antigen-presenting cells infected by mycobacteria has been shown to impair the maturation and function of dendritic cells.4 Because bacilli have been found in the endothelium of skin, nervous tissue, and nasal mucosa, endothelial cells are also thought to contribute to the pathogenesis of leprosy. Another pathway exploited by M leprae is the ubiquitin-proteasome pathway, by causing immune cell apoptosis and tumor necrosis factor (TNF)–alpha/IL-10 secretion.5

Other pathways that may be involved are the vitamin D receptor (VDR), transforming growth factor (TGF)–beta, and NOD2-mediated signaling pathways.6,7

A sudden increase in T-cell immunity is responsible for type I reversal reactions. Type II reactions result from activation of TNF-alpha and the deposition of immune complexes in tissues with neutrophilic infiltration and from complement activation in organs. One study found that cyclooxygenase 2 was expressed in microvessels, nerve bundles, and isolated nerve fibers in the dermis and subcutis during reversal reactions.8

Frequency

United States

Approximately 6000 patients with leprosy live in the United States. Approximately 95% of these patients acquired their disease in developing countries. In the United States, 200-300 cases of leprosy are reported each year. States with large immigrant populations (eg, California, New York, Florida) have the largest number of new cases of leprosy. Small endemic foci of leprosy exist in Texas, Louisiana, and Hawaii.

International

The worldwide prevalence of leprosy is reported to be just less than 1 case per 10,000 population. Most affected persons live in the tropics and subtropics. Six major countries in Asia, Africa, and South America have not achieved the goal of elimination (<1 case per 10,000 population). Approximately 86% of reported cases are found in 11 countries: Bangladesh, Brazil, China, Democratic Republic of the Congo, Ethiopia, India, Indonesia, Nepal, Nigeria, Philippines, and the United Republic of Tanzania. Overall, the prevalence of leprosy has decreased since the introduction of short-course MDT in 1982. The global annual detection rate for leprosy has also been declining since 2001.

Mortality/Morbidity

If severe and left untreated, leprosy can cause clinically significant and debilitating deformity. Since 1943, when sulfone was introduced as the first effective treatment for leprosy, antibiotic treatment has dramatically improved patients' outcomes. Early diagnosis and effective antimicrobial treatment can arrest and even cure leprosy.

Race

Leprosy occurs in persons of all races. African blacks have a high incidence of the tuberculoid form of leprosy. People with light skin and Chinese individuals tend to contract the lepromatous type of leprosy. Leprosy is endemic in Asia, Africa, the Pacific basin, and Latin America (excluding Chile). Leprosy is more a rural than urban disease.

Sex

In adults, the lepromatous type of leprosy is more common in men than in women after puberty, with a male-to-female ratio of 2:1. In children, the tuberculoid form of leprosy predominates and no sex preference is reported. Women tend to have a delayed presentation, which increases rates of deformity.

Age

Leprosy has a bimodal age distribution, with peaks at ages 10-14 years and 35-44 years. Leprosy is rare in infants. Children appear to be most susceptible to leprosy and tend to have the tuberculoid form.

Clinical

History

In general, leprosy affects the skin, peripheral nerves, and eyes. Systemic symptoms of leprosy are also possible. Specific symptoms vary with the severity of the disease.

Prodromal symptoms are generally so slight that leprosy is not recognized until a cutaneous eruption is present. However, 90% of patients have a history of numbness first, sometimes years before the skin lesions appear.

Temperature is the first sensation that is lost. Patients cannot sense extremes of hot or cold. The next sensation lost is light touch, then pain, and, finally, deep pressure. These losses are especially apparent in the hands and feet; therefore, the chief complaint may be a burn or ulcer in an anesthetic extremity.

Other parts of the body that might be affected by leprosy are the cool areas, which can include superficial peripheral nerves, the anterior chamber of the eyes, the testes, the chin, malar eminences, earlobes, and knees. From this stage of leprosy, most lesions evolve into the tuberculoid, borderline, or lepromatous types.

Physical

Assess for physical signs of leprosy in 3 general areas: cutaneous lesions, neuropathies, and eyes.

For cutaneous lesions, assess the number and distribution of skin lesions. A hypopigmented macule with a raised border is often the first cutaneous lesion. Plaques are also common. Lesions may or may not be hypoesthetic. Lesions on the buttocks often indicate borderline disease.

Regarding neuropathies, assess for areas of hypoesthesia (light touch, pinprick, temperature and anhidrosis), especially peripheral nerve trunks and cutaneous nerves. The most common nerve affected is the posterior tibial nerve. Others commonly damaged are the ulnar, median, lateral popliteal, and facial nerves. Besides sensory loss, patients may have associated tenderness and motor loss. Nerve palpation, monofilament testing, and voluntary muscle testing are the most useful clinical tests for detecting nerve damage.9

Eye damage is most often seen with facial lesions. Lagophthalmos (inability to close the eye), a late finding in persons with lepromatous leprosy, results from involvement of the zygomatic and temporal branches of the facial nerve (cranial nerve [CN] VII). Involvement of the ophthalmic branch of the trigeminal nerve (CN V) can result in reduced corneal reflex, leaving dry eyes and reduced blinking.

  • Clinical tests: Certain tests can be performed in the clinic to aid in the diagnosis of leprosy. 
    • Tissue smear testing/slit-skin smears: An incision is made in the skin, and the scalpel blade is used to obtain fluid from a lesion. The fluid is placed on a glass slide and stained by using the Ziehl-Neelsen acid-fast method or the Fite method to look for organisms. The bacterial index (BI) is then determined as the number of organisms at 100X with oil immersion. Skin smears have high specificity but low sensitivity because 70% of all patients with leprosy have negative smear results. However, this test is useful because it detects the most infectious patients.
    • Histamine testing: This test is used to diagnose postganglionic nerve injury. Histamine diphosphate is dropped on healthy skin and affected skin, and a pinprick is made through each site. The site forms a wheal on healthy skin, but not on skin where nerve damage is present.
    • Methacholine sweat testing: An intradermal injection of methacholine demonstrates the absence of sweating in leprous lesions. This test is useful in dark-skinned patients in whom the flare with the histamine test cannot be seen.
  • Diagnostic criteria for leprosy10 : The diagnosis of leprosy is primarily a clinical one. In one Ethiopian study, the following criteria had a sensitivity of 97% with a positive predictive value of 98% in diagnosing leprosy. Diagnosis was based on 1 or more of the 3 following signs: 
    • Hypopigmented or reddish patches with definite loss of sensation
    • Thickened peripheral nerves
    • Acid-fast bacilli on skin smears or biopsy material
  • Classification11 : The Ridley-Jopling classification is used to differentiate types of leprosy and helps in determining the prognosis. Purely neuritic leprosy (asymmetrical peripheral neuropathies with no evident skin lesions), with or without tenosynovitis and symmetric polyarthritis, is also possible.12 A general classification of disease is based on the number of skin lesions present and the number of bacilli found on tissue smears. Paucibacillary disease (indeterminate leprosy and tuberculoid leprosy) has fewer than 5 lesions and no bacilli on smear testing. Five or more lesions with or without bacilli (borderline leprosies and lepromatous leprosy) is considered multibacillary disease. 
    • Indeterminate leprosy: This early form causes one to a few hypopigmented or, sometimes, erythematous macules. Sensory loss is unusual. Approximately 75% of affected persons have lesions that heal spontaneously. In some, the disease may persist in this indeterminate form. In those with weak immunity, the disease progresses to one of the other forms.
    • Tuberculoid leprosy: Skin lesions are few. One erythematous large plaque is usually present, with well-defined borders that are elevated and that slope down into an atrophic center. The lesions can become arciform or annular. They can be found on the face, limbs, or elsewhere, but they spare intertriginous areas and the scalp. Lesions can be dry and scaly, hypohidrotic, and hairless. Another presentation involves a large, asymmetric hypopigmented macule. Both types of lesions are anesthetic and involve alopecia. 
      • Spontaneous resolution can occur in a few years, leaving pigmentary disturbances or scars. Progression can also occur, leading to borderline-type leprosy. In rare instances in which a patient is untreated for many years, the lepromatous type can develop.
      • Neural involvement is common in persons with tuberculoid leprosy; it leads to tender, thickened nerves with subsequent loss of function. The great auricular, common peroneal, ulnar, and radial cutaneous and posterior tibial nerves are often prominent. Nerve damage can happen early, resulting in wrist drop or foot drop.
    • Borderline tuberculoid leprosy: Lesions in this form are similar to those in the tuberculoid form, but they are smaller and more numerous. The nerves are less enlarged and alopecia is less in borderline tuberculoid leprosy than in other forms. Disease can remain in this stage, it can convert back to the tuberculoid form, or it can progress to lepromatous leprosy.
    • Borderline borderline leprosy: Cutaneous lesions consist of numerous, red, irregularly shaped plaques that are less well defined than those in the tuberculoid type. Their distribution may mimic those of the lepromatous type, but they are relatively asymmetric. Anesthesia is only moderate. Regional adenopathy may be present. Disease may remain in this stage, it may improve, or it may worsen.
    • Borderline lepromatous leprosy: Lesions are numerous and consist of macules, papules, plaques, and nodules. Annular punched-out–appearing lesions that look like inverted saucers are common. Anesthesia is often absent. As with the other forms of borderline leprosy, the disease may remain in this stage, it may improve, or it may regress.
    • Lepromatous leprosy: Early cutaneous lesions consist mainly of pale macules. Late infiltrations are present with numerous bacilli. Macular lesions are small, diffuse, and symmetric. The skin may be smooth and shiny, but skin changes do not occur in lepromatous leprosy until late in the course. Therefore, early lepromatous leprosy lesions have little or no loss of sensation, nerves are not thickened, and sweating is normal. Nerve loss is slow and progressive. 
      • Hypoesthesia occurs first over extensor surfaces of the distal extremities, followed by weakness in the same areas.
      • Alopecia affects the lateral aspects of the eyebrows (madarosis), spreading to the eyelashes and then the trunk. Scalp hair remains intact.
      • Lepromatous infiltrations can be diffuse, can occur as nodules (called lepromas), or can be plaques. The diffuse type results in the thickened skin appearance of a leonine facies. Neuritic lesions are symmetric and slow to develop.
      • Eye involvement occurs, causing pain, photophobia, decreased visual acuity, glaucoma, and blindness.
      • Nasal infiltration can cause a saddle-nose deformity and impaired olfaction. Hoarseness ("leprous huskiness") and stridor are a result of laryngeal involvement.13
      • Oral lepromas, usually located on the hard and soft palate, uvula, tongue ("cobblestoning"), lips, and gums, can progress to necrosis and ulceration. Tissue destruction may result.14
      • Infiltration of the helix or megalobule (elongation and wrinkling of the earlobe) may occur.
      • Lymphadenopathy and hepatomegaly can result from organ infiltration.
      • Aseptic necrosis and osteomyelitis can occur with repeated trauma after joint invasion.
      • Brawny edema of the lower extremities is a late finding.
      • Unlike the other types of leprosy, lepromatous leprosy cannot convert back to the less severe borderline or tuberculoid types of disease.
    • Histoid leprosy is a recognized clinical variant of lepromatous leprosy.15 It can occur as a result of M leprae resistance to monotherapy of MDT. Reports of de novo histoid leprosy suggest that it may also possibly evolve from borderline or indeterminate leprosy. Paucibacillary and multibacillary forms also exist. They may present as firm plaques or nodules. The lesions may occur on the thighs/buttocks, back, face, and extremities, especially bony areas like the elbows and knees. Eyebrows and nasal cartilage are usually spared.
    • Other: Lepra reactions are complications that occur in 50% of patients after the start of therapy or occasionally before therapy (see Complications).

Causes

Leprosy is caused by M leprae, an obligate intracellular, acid-fast, gram-positive bacillus.

  • Most persons are immune to leprosy. Subclinical disease is common in endemic areas, and the infection progresses to clinical disease in only a select few. 
    • Exposure to the nasal discharge of individuals who remain untreated for years is thought to be the main cause of infection. Transmission is not completely understood.
    • In addition to exposure to respiratory secretions, exposure to insect vectors and infected soil has been suspected as a possible mode of transmission.
    • In endemic countries, household contacts of patients are at increased risk for contracting leprosy. The relative risk is 8-10 times for lepromatous leprosy and 2-4 times for tuberculoid leprosy. In nonendemic countries, household contacts rarely acquire the disease.
    • HIV infection is not a risk factor for acquiring leprosy, nor does it increase the clinical symptoms or virulence of leprosy. However, latent cases of leprosy infections may emerge as part of the immune reconstitution inflammatory syndrome after starting highly active antiretroviral therapy.16,17
    • One report describes 2 cases of leprosy developing after treatment with infliximab.18 Both patients developed type I reversal reactions after stopping the TNF-alpha inhibitor. Another patient developed a type I reversal reaction after stopping adalimumab therapy, despite no prior diagnosis of leprosy.19
    • Several cases of tattoo inoculation leprosy have been reported, most in India.20
    • Leprosy has been reported in conjunction with visceral leishmaniasis (kala-azar).
  • The following genes have been associated with leprosy; hence, susceptibility to leprosy may be at least partially inheritable7 :
    • Susceptible loci have been found on band 10p13 and chromosome 6.
    • Associations include HLA-DR2 and HLA-DR3 (tuberculoid disease), as well as HLA-DQ1 (lepromatous leprosy).
    • HLA-DRB1*04 is associated with resistance, and HLA-DRB1*10 is associated with susceptibility to leprosy in Brazilian and Vietnamese patients.21
    • Genetic variants have been found in the shared promoter region of the PARK2 (parkin) and PACRG genes expressed on monocytes.
    • Lymphotoxin-alpha (LTA) + 80 expressed on dendritic cells appears to be a risk factor for early-onset leprosy, independent of PARK2/PARCG and HLA class I and HLA-DRB1 genes.22,23
    • Polymorphisms in the gene promoter regions of TNF (multibacillary leprosy) and IL-10 (-819T allele) are noted in leprosy susceptibility.
    • Mutations in TLR1 and TLR2 may be involved in susceptibility and/or resistance to other infectious diseases.
    • Polymorphisms in the NRAMP1 gene appear on macrophages in multibacillary disease in African patients.
    • TaqI polymorphism (tt genotype) at exon 9 of the vitamin D receptor gene is noted.24

More on Leprosy

Overview: Leprosy
Differential Diagnoses & Workup: Leprosy
Treatment & Medication: Leprosy
Follow-up: Leprosy
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Han XY, Sizer KC, Thompson EJ, et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol. Oct 2009;191(19):6067-74. [Medline].

  2. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol. Jul 2005;125(1):1-8. [Medline].

  3. Tapinos N, Ohnishi M, Rambukkana A. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med. Aug 2006;12(8):961-6. [Medline].

  4. Makino M, Maeda Y, Mukai T, Kaufmann SH. Impaired maturation and function of dendritic cells by mycobacteria through IL-1beta. Eur J Immunol. Jun 2006;36(6):1443-52. [Medline].

  5. Fulco TO, Lopes UG, Sarno EN, Sampaio EP, Saliba AM. The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion. Immunol Lett. May 15 2007;110(1):82-5. [Medline].

  6. Goulart LR, Goulart IM. Leprosy pathogenetic background: a review and lessons from other mycobacterial diseases. Arch Dermatol Res. Feb 2009;301(2):123-37. [Medline].

  7. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med. Dec 31 2009;361(27):2609-18. [Medline].

  8. Pesce C, Grattarola M, Menini S, Fiallo P. Cyclooxygenase 2 expression in vessels and nerves in reversal reaction leprosy. Am J Trop Med Hyg. Jun 2006;74(6):1076-7. [Medline].

  9. Khambati FA, Shetty VP, Ghate SD, Capadia GD. Sensitivity and specificity of nerve palpation, monofilament testing and voluntary muscle testing in detecting peripheral nerve abnormality, using nerve conduction studies as gold standard; a study in 357 patients. Lepr Rev. Mar 2009;80(1):34-50. [Medline].

  10. Britton WJ, Lockwood DN. Leprosy. Lancet. Apr 10 2004;363(9416):1209-19. [Medline].

  11. Ishii N. Recent advances in the treatment of leprosy. Dermatol Online J. Mar 2003;9(2):5. [Medline]. [Full Text].

  12. Haroon N, Agarwal V, Aggarwal A, Kumari N, Krishnani N, Misra R. Arthritis as presenting manifestation of pure neuritic leprosy--a rheumatologist's dilemma. Rheumatology (Oxford). Apr 2007;46(4):653-6. [Medline].

  13. Bhat R, Sharma VK, Deka RC. Otorhinolaryngologic manifestations of leprosy. Int J Dermatol. Jun 2007;46(6):600-6. [Medline].

  14. Motta AC, Komesu MC, Silva CH, et al. Leprosy-specific oral lesions: a report of three cases. Med Oral Patol Oral Cir Bucal. Aug 1 2008;13(8):E479-82. [Medline].

  15. Sehgal VN, Srivastava G, Singh N, Prasad PV. Histoid leprosy: the impact of the entity on the postglobal leprosy elimination era. Int J Dermatol. Jun 2009;48(6):603-10. [Medline].

  16. Batista MD, Porro AM, Maeda SM, et al. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS. Clin Infect Dis. Mar 15 2008;46(6):e56-60. [Medline].

  17. Menezes VM, Sales AM, Illarramendi X, et al. Leprosy reaction as a manifestation of immune reconstitution inflammatory syndrome: a case series of a Brazilian cohort. AIDS. Mar 13 2009;23(5):641-3. [Medline].

  18. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis. Jul 15 2006;43(2):e19-22. [Medline].

  19. Camacho ID, Valencia I, Rivas MP, Burdick AE. Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy. Arch Dermatol. Mar 2009;145(3):349-51. [Medline].

  20. Ghorpade A. Ornamental tattoos and skin lesions. Tattoo inoculation borderline tuberculoid leprosy. Int J Dermatol. Jan 2009;48(1):11-3. [Medline].

  21. Vanderborght PR, Pacheco AG, Moraes ME, et al. HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun. Jun 2007;8(4):320-4. [Medline].

  22. Alter A, Alcaïs A, Abel L, Schurr E. Leprosy as a genetic model for susceptibility to common infectious diseases. Hum Genet. Apr 2008;123(3):227-35. [Medline].

  23. Schurr E, Alcaïs A, de Leseleuc L, Abel L. Genetic predisposition to leprosy: A major gene reveals novel pathways of immunity to Mycobacterium leprae. Semin Immunol. Dec 2006;18(6):404-10. [Medline].

  24. Goulart LR, Ferreira FR, Goulart IM. Interaction of TaqI polymorphism at exon 9 of the vitamin D receptor gene with the negative lepromin response may favor the occurrence of leprosy. FEMS Immunol Med Microbiol. Oct 2006;48(1):91-8. [Medline].

  25. Bhushan P, Sardana K, Koranne RV, Choudhary M, Manjul P. Diagnosing multibacillary leprosy: a comparative evaluation of diagnostic accuracy of slit-skin smear, bacterial index of granuloma and WHO operational classification. Indian J Dermatol Venereol Leprol. Jul-Aug 2008;74(4):322-6. [Medline].

  26. Silva EA, Iyer A, Ura S, et al. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health. Dec 2007;12(12):1450-8. [Medline].

  27. Parkash O, Kumar A, Pandey R, Nigam A, Girdhar BK. Performance of a lateral flow test for the detection of leprosy patients in India. J Med Microbiol. Jan 2008;57:130-2. [Medline].

  28. Parkash O, Kumar A, Pandey R, Franken KL, Ottenhoff TH. Detection of Mycobacterium leprae infection employing a combinatorial approach of anti-45 kDa and modified anti-PGL-I antibody detection assays. J Med Microbiol. Aug 2007;56:1129-30. [Medline].

  29. Bang PD, Suzuki K, Phuong le T, Chu TM, Ishii N, Khang TH. Evaluation of polymerase chain reaction-based detection of Mycobacterium leprae for the diagnosis of leprosy. J Dermatol. May 2009;36(5):269-76. [Medline].

  30. Phetsuksiri B, Rudeeaneksin J, Supapkul P, Wachapong S, Mahotarn K, Brennan PJ. A simplified reverse transcriptase PCR for rapid detection of Mycobacterium leprae in skin specimens. FEMS Immunol Med Microbiol. Dec 2006;48(3):319-28. [Medline].

  31. Rothschild BM, Rothschild C. Skeletal manifestations of leprosy: analysis of 137 patients from different clinical settings in the pre- and post-modern treatment eras. J Clin Rheumatol. Aug 2001;7(4):228-37. [Medline].

  32. Gupta SK, Nigam S, Mandal AK, Kumar V. S-100 as a useful auxiliary diagnostic aid in tuberculoid leprosy. J Cutan Pathol. Jul 2006;33(7):482-6. [Medline].

  33. Reddy RR, Singh G, Sacchidanand S, et al. A comparative evaluation of skin and nerve histopathology in single skin lesion leprosy. Indian J Dermatol Venereol Leprol. Nov-Dec 2005;71(6):401-5. [Medline].

  34. World Health Organization. WHO-recommended MDT regimens. World Health Organization. Available at http://www.who.int/lep/mdt/regimens/en/.

  35. Jing Z, Zhang R, Zhou D, Chen J. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy. Lepr Rev. Jun 2009;80(2):170-6. [Medline].

  36. Bureau of Primary Health Care. Standard treatment regimens. US Department of Health and Human Services. Health Resources and Services Administration. Available at http://www.hrsa.gov/hansens/clinical/regimens.htm.

  37. Sapkota BR, Shrestha K, Pandey B, Walker SL. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. Lepr Rev. Dec 2008;79(4):425-8. [Medline].

  38. Fabi SG, Hill C, Witherspoon JN, Boone SL, West DP. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. J Drugs Dermatol. Aug 2009;8(8):765-9. [Medline].

  39. Moet FJ, Pahan D, Oskam L, Richardus JH. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. Apr 5 2008;336(7647):761-4. [Medline].

  40. Smith WC. Chemoprophylaxis in the prevention of leprosy. BMJ. Apr 5 2008;336(7647):730-1. [Medline].

  41. Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev. Mar 2006;77(1):25-33. [Medline].

  42. Safa G, Darrieux L, Coic A, Tisseau L. Type 1 leprosy reversal reaction treated with topical tacrolimus along with systemic corticosteroids. Indian J Med Sci. Aug 2009;63(8):359-62. [Medline].

  43. Aires NB, Refkalefsky Loureiro W, Villela MA, Sakai Valente NY, Trindade MA. Sweet's syndrome type leprosy reaction. J Eur Acad Dermatol Venereol. Apr 2009;23(4):467-9. [Medline].

  44. Chauhan S, D'Cruz S, Mohan H, Singh R, Ram J, Sachdev A. Type II lepra reaction: an unusual presentation. Dermatol Online J. Jan 27 2006;12(1):18. [Medline].

  45. Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. Aug 17 2006;355(7):739. [Medline].

  46. Costa IM, Kawano LB, Pereira CP, Nogueira LS. Lucio's phenomenon: a case report and review of the literature. Int J Dermatol. Jul 2005;44(7):566-71. [Medline].

  47. Crawford CL. No role for thalidomide in the treatment of leprosy. J Infect Dis. Jun 15 2006;193(12):1743-4; author reply 1744-5. [Medline].

  48. Sena CB, Salgado CG, Tavares CM, Da Cruz CA, Xavier MB, Do Nascimento JL. Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor. Lepr Rev. Jun 2006;77(2):121-9. [Medline].

  49. Nashed SG, Rageh TA, Attallah-Wasif ES, Abd-Elsayed AA. Intraneural injection of corticosteroids to treat nerve damage in leprosy: a case report and review of literature. J Med Case Reports. Dec 9 2008;2:381. [Medline].

  50. Rath S, Schreuders TA, Selles RW. Early postoperative active mobilisation versus immobilisation following tibialis posterior tendon transfer for foot-drop correction in patients with Hansen's disease. J Plast Reconstr Aesthet Surg. Feb 19 2009;[Medline].

  51. Shah RK. Tibialis posterior transfer by interosseous route for the correction of foot drop in leprosy. Int Orthop. Dec 2009;33(6):1637-40. [Medline].

  52. Kanaji A, Higashi M, Namisato M, Nishio M, Ando K, Yamada H. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Lepr Rev. Jun 2006;77(2):147-53. [Medline].

  53. Pereira HL, Ribeiro SL, Pennini SN, Sato EI. Leprosy-related joint involvement. Clin Rheumatol. Jan 2009;28(1):79-84. [Medline].

  54. Drug resistance in leprosy: reports from selected endemic countries. Wkly Epidemiol Rec. Jun 26 2009;84(26):264-7. [Medline].

  55. Ludwig RJ, Henke U, Wolter M, et al. Persistence of peri-neural granulomas after successful treatment of leprosy. J Eur Acad Dermatol Venereol. Nov 2007;21(10):1414-6. [Medline].

  56. Sales AM, de Matos HJ, Nery JA, Duppre NC, Sampaio EP, Sarno EN. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Braz J Med Biol Res. Feb 2007;40(2):243-8. [Medline].

  57. Araoz R, Honore N, Cho S, et al. Antigen discovery: a postgenomic approach to leprosy diagnosis. Infect Immun. Jan 2006;74(1):175-82. [Medline].

  58. Barker LP. Mycobacterium leprae interactions with the host cell: recent advances. Indian J Med Res. Jun 2006;123(6):748-59. [Medline].

  59. Chimenos Kustner E, Pascual Cruz M, Pinol Dansis C, Vinals Iglesias H, Rodríguez de Rivera Campillo ME, Lopez Lopez J. Lepromatous leprosy: a review and case report. Med Oral Patol Oral Cir Bucal. Nov 1 2006;11(6):E474-9. [Medline].

  60. Dayal R, Singh SP, Mathur PP, Katoch VM, Katoch K, Natrajan M. Diagnostic value of in situ Polymerase Chain Reaction in leprosy. Indian J Pediatr. Dec 2005;72(12):1043-6. [Medline].

  61. Global leprosy situation, 2006. Wkly Epidemiol Rec. Aug 11 2006;81(32):309-16. [Medline].

  62. Jacobson RR, Krahenbuhl JL. Leprosy. Lancet. Feb 20 1999;353(9153):655-60. [Medline].

  63. Leal AM, Foss NT. Endocrine dysfunction in leprosy. Eur J Clin Microbiol Infect Dis. Jan 2009;28(1):1-7. [Medline].

  64. Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol. Sep 2004;51(3):417-26. [Medline].

  65. Rai VM, Balachandran C. Necrotic erythema nodosum leprosum. Dermatol Online J. Mar 30 2006;12(3):12. [Medline].

  66. Ramos-e-Silva M, Ribeiro de Castro MC. Mycobacterial infections. In: Bolognia, Jorizzo, Rapini, eds. Dermatology. Vol 1. Philadelphia, Pa: Mosby; 2003:1145-52.

  67. Rinaldi A. The global campaign to eliminate leprosy. PLoS Med. Dec 2005;2(12):e341. [Medline].

  68. Sehgal VN. Spontaneous appearances of papules, nodules, and/or plaques: a prelude to abacillary, paucibacillary, or multibacillary histoid leprosy. Skinmed. May-Jun 2006;5(3):139-41. [Medline].

  69. Walker SL, Lockwood DN. Leprosy. Clin Dermatol. Mar-Apr 2007;25(2):165-72. [Medline].

  70. Yoder LJ, Guerra IE. Hansen's Disease: A Guide to Management in the United States. Carville, La: Hansen's Disease Foundation; 1996:18-22.

[ CLOSE WINDOW ]

Keywords

leprosy, Hansen's disease, Hansen disease, indeterminate leprosy, tuberculoid leprosy, borderline tuberculoid leprosy, borderline borderline leprosy, borderline lepromatous leprosy, lepromatous leprosy, lepra reaction, reversal reaction, erythema nodosum leprosum, ENL, Lucio phenomenon

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Felisa S Lewis, MD,, Staff Physician, Department of Dermatology, Madigan Army Medical Center
Felisa S Lewis, MD, is a member of the following medical societies: American Academy of Dermatology, International Society of Dermatology, and Women's Dermatologic Society
Disclosure: Nothing to disclose.

Coauthor(s)

Theresa Dressler Conologue, DO, FAAD, Physician, Department of Dermatology, Geisinger Medical Center
Theresa Dressler Conologue, DO, FAAD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, and American Society for Laser Medicine and Surgery
Disclosure: Nothing to disclose.

Elyse Harrop, MD, Clinical Instructor, Department of Dermatology, Metrohealth Medical Center
Elyse Harrop, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

Terry L Barrett, MD, Clinical Professor of Dermatology and Pathology, University of Texas Southwestern School of Medicine; Director, ProPath Dermatopathology, Dallas, Texas
Terry L Barrett, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Medical Association, American Society of Dermatopathology, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory
Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania
Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.